Slow Capital, Inc. Exact Sciences Corp Transaction History

Slow Capital, Inc.

$645 Million
Q3 2024

A detailed history of Slow Capital, Inc. transactions in Exact Sciences Corp stock. As of the latest transaction made, Slow Capital, Inc. holds 76,655 shares of EXAS stock, worth $4.61 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares

76,655

Previous 72,812 5.28%

Holding current value

$4.61 Million

Previous $3.08 Million 69.67%

% of portfolio

0.81%

Previous 0.5%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$42.43 - $70.83 $163,058 - $272,199	3,843 Added 5.28%	76,655 $5.22 Million
Q2 2024 Jul 24, 2024	BUY	$41.33 - $74.26 $124,403 - $223,522	3,010 Added 4.31%	72,812 $3.08 Million
Q1 2024 Apr 17, 2024	BUY	$56.27 - $73.77 $251,133 - $329,235	4,463 Added 6.83%	69,802 $4.82 Million
Q4 2023 Jan 30, 2024	SELL	$59.06 - $75.72 $65,792 - $84,352	-1,114 Reduced 1.68%	65,339 $4.83 Million
Q3 2023 Oct 19, 2023	SELL	$65.94 - $99.04 $104,119 - $156,384	-1,579 Reduced 2.32%	66,453 $4.53 Million
Q2 2023 Aug 09, 2023	SELL	$62.68 - $95.05 $138,397 - $209,870	-2,208 Reduced 3.14%	68,032 $6.39 Million
Q1 2023 Apr 26, 2023	SELL	$47.19 - $70.77 $2,784 - $4,175	-59 Reduced 0.08%	70,240 $4.76 Million
Q4 2022 Feb 13, 2023	BUY	$30.35 - $53.15 $59,577 - $104,333	1,963 Added 2.87%	70,299 $3.48 Million
Q3 2022 Oct 27, 2022	BUY	$31.97 - $49.37 $438,308 - $676,862	13,710 Added 25.1%	68,336 $2.22 Million
Q2 2022 Jul 28, 2022	BUY	$35.61 - $76.23 $1.95 Million - $4.16 Million	54,626 New	54,626 $2.15 Million

Others Institutions Holding EXAS

# of Institutions

672

Shares Held

163M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.6B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Slow Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Slow Capital, Inc. with notifications on news.

Account